Cellectis S.A.
CLLS
$3.62
$0.123.43%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -18.24% | 117.11% | 107.48% | 135.31% | 4,393.29% |
| Total Other Revenue | -26.09% | 7.68% | 1.80% | -30.30% | 43.47% |
| Total Revenue | -19.51% | 105.89% | 91.44% | 85.10% | 662.06% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -19.51% | 105.89% | 91.44% | 85.10% | 1,110.30% |
| SG&A Expenses | -2.64% | 0.79% | 30.81% | -7.88% | 5.59% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 580.85% | 12.00% | 44.90% | -1,117.14% | 4,600.00% |
| Total Operating Expenses | 14.37% | 1.05% | 3.99% | -4.33% | -14.89% |
| Operating Income | -62.46% | 174.65% | 44.30% | 32.14% | 62.36% |
| Income Before Tax | -515.49% | 102.55% | 6.78% | -436.89% | 115.40% |
| Income Tax Expenses | -182.30% | -- | -- | -- | 8,466.67% |
| Earnings from Continuing Operations | -544.41% | 102.55% | 6.07% | -421.25% | 114.17% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -544.41% | 102.55% | 6.07% | -421.25% | 114.17% |
| EBIT | -62.46% | 174.65% | 44.30% | 32.14% | 62.36% |
| EBITDA | -105.70% | 239.56% | 55.36% | 39.30% | 71.02% |
| EPS Basic | -543.07% | 102.56% | 14.29% | -330.28% | 109.24% |
| Normalized Basic EPS | -228.65% | 102.56% | 14.92% | -341.67% | 148.41% |
| EPS Diluted | -562.61% | 102.56% | 14.29% | -20.67% | 108.85% |
| Normalized Diluted EPS | -228.65% | 102.49% | 14.92% | -446.93% | 148.41% |
| Average Basic Shares Outstanding | 0.23% | 0.23% | 9.58% | 39.47% | 53.44% |
| Average Diluted Shares Outstanding | 0.23% | 1.61% | 9.58% | -2.85% | 53.44% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |